Nutlin's two roads toward apoptosis.

摘要

The applications of genotoxic chemotherapies are often limited by their systemic toxicity and the development of multi-drug resistance. One of the current major objectives of cancer research is, therefore, to discover non-genotoxic drugs that are able to effectively eliminate tumor cells with minimum side effects to patients. It's no surprise then that Nutlin, which was the first potent MDM2-p53 inhibitor, reported by Vassilev, et al. in 2004, and represents non-genotoxic drugs, has been the focus of active, intense and ongoing research in the field of p53 and cancer therapy.